PillDextrose Monohydrate
Brands: Dextrose · Dextrose Monohydrate
11 active makers
soon
soon
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it11 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Baxter Healthcare Corporation | unknown | 26 | SUPPLYING |
| Fresenius Kabi USA, LLC | unknown | 17 | SUPPLYING |
| ICU Medical Inc. | unknown | 15 | SUPPLYING |
| BECTON DICKINSON AND COMPANY | unknown | 11 | SUPPLYING |
| Hospira, Inc. | unknown | 5 | SUPPLYING |
| Medical Purchasing Solutions, LLC | unknown | 5 | SUPPLYING |
| HF Acquisition Co LLC, DBA HealthFirst | unknown | 3 | SUPPLYING |
| ProPharma Distribution | unknown | 2 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 2 | SUPPLYING |
| Henry Schein Inc. | unknown | 2 | SUPPLYING |
| International Medication Systems, Limited | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 11, 2026RECALLRecall (Class II): 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL freeflex bag, Fresenius Kabi USA, LLC ("…
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
- Mar 11, 2026RECALLRecall (Class II): 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fre…
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
- Mar 11, 2026RECALLRecall (Class II): 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fre…
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
- Oct 11, 2024SHORTAGEDrug shortage: Dextrose Monohydrate 70% Injection (Baxter Healthcare)
Dextrose Monohydrate 70% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Mar 1, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 10% Injection (Otsuka ICU Medical LLC)
Dextrose Monohydrate 10% Injection — reported in shortage by Otsuka ICU Medical LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Mar 1, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 10% Injection (Fresenius Kabi USA, LLC)
Dextrose Monohydrate 10% Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Mar 1, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 10% Injection (Baxter Healthcare)
Dextrose Monohydrate 10% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Feb 14, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 5% Injection (Baxter Healthcare)
Dextrose Monohydrate 5% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Feb 14, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 5% Injection (Otsuka ICU Medical LLC)
Dextrose Monohydrate 5% Injection — reported in shortage by Otsuka ICU Medical LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Feb 14, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 5% Injection (Fresenius Kabi USA, LLC)
Dextrose Monohydrate 5% Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
- Jan 13, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 50% Injection (Hospira, Inc., a Pfizer Company)
Dextrose Monohydrate 50% Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Pediatric.
- Jan 13, 2022SHORTAGEDrug shortage: Dextrose Monohydrate 50% Injection (Amphastar Pharmaceuticals, Inc.)
Dextrose Monohydrate 50% Injection — reported in shortage by Amphastar Pharmaceuticals, Inc.. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Pediatric.
- Nov 30, 2021RECALLRecall (Class II): 5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, N…
Lack of sterility assurance: bag has the potential to leak. — Recalling firm: Pfizer Inc. — USA Nationwide
- Nov 27, 2019RECALLRecall (Class II): 25% Dextrose Injection, USP 2.5 grams (250 mg/mL) 10 mL Single-dose, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA,…
Labeling: Incorrect or Missing Lot and/or expiration date. — Recalling firm: Pfizer Inc. — Nationwide within the United States including Puerto Rico.
- Jul 6, 2017RECALLRecall (Class II): 5% Dextrose Injection, USP, 100 mL VIAFLEX Plastic Container, Rx only, Baxter Healthcare Corporation, Deerfield IL 600…
Lack of Assurance of Sterility: Bags have the potential to leak. — Recalling firm: Baxter Healthcare Corporation — Nationwide, Puerto Rico and Saudi Arabia
- Apr 21, 2017RECALLRecall (Class I): Infant 25% DEXTROSE Injection, USP, 2.5 g (250 mg/mL), 10 mL Unit of Use Single-dose Syringe per carton, Rx only, Hospi…
Presence of Particulate Matter: human hair found within an internal sample syringe. — Recalling firm: Hospira Inc. — Nationwide in the USA and Puerto Rico
- Dec 15, 2015RECALLRecall (Class I): Dextrose Injection,USP,70% 2000 mL VIAFLEX Plastic Container Bag, Pharmacy Bulk Package, Not For Direct Infusion, Must …
Presence of Particulate Matter: Confirmed customer compliants of finding an insect floating in the primary container of each product. — Recalling firm: Baxter Healthcare Corp. — Nationwide
- Mar 24, 2015RECALLRecall (Class I): 10% Dextrose Injection, USP, 250mL VIAFLEX Plastic bags, Manufactured by Baxter Healthcare Corporation 65 Pitts Statio…
Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) — Recalling firm: Baxter Healthcare Corp. — US, Puerto Rico, and Bermuda
- Mar 24, 2015RECALLRecall (Class I): 5% Dextrose Injection, USP, 250mL VIAFLEX Plastic bags, Manufactured by Baxter Healthcare Corporation 65 Pitts Station …
Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) — Recalling firm: Baxter Healthcare Corp. — US, Puerto Rico, and Bermuda
- Mar 18, 2015RECALLRecall (Class II): 5% Dextrose Injection, USP, 1000mL in VIAFLEX Plastic Container, Rx only, Manufactured by Baxter Healthcare Corp., Nort…
Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which may compromise product sterility. — Recalling firm: Baxter Healthcare Corp. — Nationwide
- Mar 5, 2015RECALLRecall (Class II): 5% DEXTROSE Injection, USP, 250 mL ADD-Vantage Unit bag (NDC 0409-7100-02), UPC (01)0030404097100026; packaged in 24 ba…
Lack of Assurance of Sterility: there is a potential for solution to leak at the administrative port of the primary container. — Recalling firm: Hospira Inc. — Nationwide
- Nov 21, 2013RECALLRecall (Class I): 5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deer…
Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag — Recalling firm: Baxter Healthcare Corp. — Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.
- May 21, 2013RECALLRecall (Class II): 5% Dextrose Injection, USP, in VIAFLEX Plastic Container Multi Pack, Rx Only, a) 50 mL (NDC 0338-0017-31), b) 100 mL (N…
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port. — Recalling firm: Baxter Healthcare Corp. — Nationwide & Puerto Rico